

Öğr. Gör. Dr. DENİZ CANSEN KAHRAMAN

Kişisel Bilgiler

İş Telefonu: [+90 0312 210 7374](tel:+9003122107374)

E-posta: cansen@metu.edu.tr

Web: <https://avesis.metu.edu.tr/cansen>

Uluslararası Araştırmacı ID'leri

ScholarID: 2S70xr4AAAAJ

ORCID: 0000-0002-3381-5463

Publons / Web Of Science ResearcherID: O-7515-2017

ScopusID: 57193092535

Yoksis Araştırmacı ID: 318049

Eğitim Bilgileri

2011 - 2018	Doktora, İhsan Doğramacı Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik Bölümü, Türkiye
2007 - 2011	Lisans, İhsan Doğramacı Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik Bölümü, Türkiye

Yabancı Diller

İngilizce, C1 İleri

Araştırma Alanları

Moleküler Biyoloji ve Genetik, Kanser Moleküler Biyolojisi

Akademik Unvanlar / Görevler

2020 - Devam Ediyor	Öğretim Görevlisi Dr., Orta Doğu Teknik Üniversitesi, Enformatik Enstitüsü, Sağlık Bilişimi Anabilim Dalı
---------------------	---

Verdiği Dersler

2019 - 2020	APPLICATIONS OF BIOINFORMATICS IN MOLECULAR BIOLOGY, Yüksek Lisans
-------------	--

Yönetilen Tezler

2023	Kahraman D. C., Muyan M., Yüksek Lisans, E.AKAR(Öğrenci), MECHANISMS OF SYNERGISTIC ANTITUMOR EFFECT OF NAPROXEN AND SORAFENIB IN HEPATOCELLULAR CARCINOMA
2022	Kahraman D. C., Muyan M., Yüksek Lisans, N.ECE(Öğrenci), IN VITRO AUTOCRINE SECRETION OF INFLAMMATORY CYTOKINES IN RESPONSE TO DRUG STRESS IN HCC AND LCSC POPULATIONS
2021	Kahraman D. C., Muyan M., Yüksek Lisans, B.BINARCI(Öğrenci), BIOACTIVITY ANALYSIS OF NOVEL INDOLE DERIVATIVES ON HEPATOCELLULAR CARCINOMA AS SIRTUIN INHIBITORS

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Design, synthesis, and evaluation of novel Indole-Based small molecules as sirtuin inhibitors with anticancer activities.**
Binarci B., Kilic E. K., Dogan T., Cetin Atalay R., Kahraman D. C., Nacak Baytas S.
Drug development research, cilt.85, sa.7, 2024 (SCI-Expanded)
- II. **Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors**
Hawash M., Jaradat N., Abualhasan M., ŞÜKÜROĞLU M. K., Qaoud M. T., KAHRAMAN D. C., Daraghmeh H., Maslamani L., Sawafta M., Ratrout A., et al.
BMC Chemistry, cilt.17, sa.1, 2023 (SCI-Expanded)
- III. **Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies**
Hawash M., Ergun S. G., KAHRAMAN D. C., OLĞAÇ A., Hamel E., Cetin-Atalay R., BAYTAŞ S.
Journal of Molecular Structure, cilt.1285, 2023 (SCI-Expanded)
- IV. **A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation**
KAHRAMAN D. C., Guven E. B., Aytac P. S., Aykut G., Tozkoparan B., Atalay R. C.
SCIENTIFIC REPORTS, cilt.12, sa.1, 2022 (SCI-Expanded)
- V. **Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents**
Hawash M., KAHRAMAN D. C., OLĞAÇ A., Ergun S. G., Hamel E., Cetin-Atalay R., BAYTAŞ S.
JOURNAL OF MOLECULAR STRUCTURE, cilt.1254, 2022 (SCI-Expanded)
- VI. **Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency**
Yilmaz N. S., Eltan S. B., KAYAOĞLU B., Geckin B., Heredia R. J., Sefer A. P., KIYKIM A., Nain E., Kasap N., DOĞRU Ö., et al.
JOURNAL OF CLINICAL IMMUNOLOGY, cilt.42, sa.3, ss.582-596, 2022 (SCI-Expanded)
- VII. **Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.**
Narci K., Kahraman D. C., Koyas A., Ersahin T., Tuncbag N., Atalay R. C.
BMC cancer, cilt.22, sa.1, ss.320, 2022 (SCI-Expanded)
- VIII. **Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines**
Hawash M., KAHRAMAN D. C., Ergun S. G., Cetin-Atalay R., BAYTAŞ S.
BMC CHEMISTRY, cilt.15, sa.1, 2021 (SCI-Expanded)
- IX. **Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells**
Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, cilt.221, 2021 (SCI-Expanded)
- X. **Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation**
Hawash M., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.
CHEMISTRY & BIODIVERSITY, cilt.18, sa.5, 2021 (SCI-Expanded)
- XI. **MDeePred: Novel multi-channel protein featurization for deep learning-based binding affinity prediction in drug discovery**
Rifaioglu A., Atalay R. C., KAHRAMAN D. C., DOĞAN T., Martin M., ATALAY M. V.
Bioinformatics, cilt.37, sa.5, ss.693-704, 2021 (SCI-Expanded)
- XII. **Transcriptome profiles associated with selenium-deficiency-dependent oxidative stress identify potential diagnostic and therapeutic targets in liver cancer cells**
Gozen D., KAHRAMAN D. C., Narci K., Shehwana H., KONU KARAKAYALI Ö., Cetin-Atalay R.
TURKISH JOURNAL OF BIOLOGY, cilt.45, sa.2, ss.149-164, 2021 (SCI-Expanded)

- XIII. **CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.**
Ayaz G., Razizadeh N., Yaşar P., Kars G., Kahraman D. C., Saatci Ö., Şahin Ö., Çetin-Atalay R., Muyan M.
Scientific reports, cilt.10, ss.5971, 2020 (SCI-Expanded)
- XIV. **Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment**
KAHRAMAN D. C., Kahraman T., Cetin-Atalay R.
MOLECULAR CANCER THERAPEUTICS, cilt.18, sa.11, ss.2146-2157, 2019 (SCI-Expanded)
- XV. **Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.**
Ture A., Kahraman D. C., Cetin-Atalay R., Helvacioğlu S., Charehsaz M., KÜÇÜKGÜZEL İ.
Computational biology and chemistry, cilt.78, ss.227-241, 2019 (SCI-Expanded)
- XVI. **Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.**
Inceler N., ÖZKAN Y., Turan N. N., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.
MedChemComm, cilt.9, sa.5, ss.795-811, 2018 (SCI-Expanded)
- XVII. **Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.**
Hawash M. M. A., Kahraman D. C., Eren F., Atalay R. C., BAYTAŞ S.
European journal of medicinal chemistry, cilt.129, ss.12-26, 2017 (SCI-Expanded)
- XVIII. **Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.**
Kahraman D. C., Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., Cetin-Atalay R.
MedChemComm, cilt.8, sa.1, ss.81-87, 2016 (SCI-Expanded)
- XIX. **Phase and TV Based Convex Sets for Blind Deconvolution of Microscopic Images**
Tofighi M., Yorulmaz O., Koese K., Yildirim D. C., Cetin-Atalay R., ÇETİN A. E.
IEEE JOURNAL OF SELECTED TOPICS IN SIGNAL PROCESSING, cilt.10, sa.1, ss.81-91, 2016 (SCI-Expanded)
- XX. **Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.**
Vojtickova M., Dobias J., Hanquet G., Addova G., Cetin-Atalay R., Yildirim D. C., Bohac A.
European journal of medicinal chemistry, cilt.103, ss.105-22, 2015 (SCI-Expanded)
- XXI. **Application of the Ugi reaction with multiple amino acid-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics.**
Stucchi M., Cairati S., Cetin-Atalay R., Christodoulou M. S., Grazioso G., Pescitelli G., Silvani A., Yildirim D. C., Lesma G.
Organic & biomolecular chemistry, cilt.13, sa.17, ss.4993-5005, 2015 (SCI-Expanded)
- XXII. **Near-IR absorbing BODIPY derivatives as glutathione-activated photosensitizers for selective photodynamic action.**
Turan I., Cakmak F., Yildirim D. C., Cetin-Atalay R., Akkaya E.
Chemistry (Weinheim an der Bergstrasse, Germany), cilt.20, ss.16088-92, 2014 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools**
Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., Atas H., Atalay M. V., Acar A. C., Doğan T.
JOURNAL OF GASTROINTESTINAL CANCER, cilt.52, sa.4, ss.1266-1276, 2021 (ESCI)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- Targeting sirtuins with novel indole derivatives: implications for anticancer activity in hepatocellular**

carcinoma

BINARCI B., DOĞAN T., ATALAY R., KAHRAMAN D. C., BAYTAŞ S.

EASL Liver Cancer Summit 2024, Rotterdam, Hollanda, 22 - 24 Şubat 2024

- II. **Exploring early markers of fibrosis progression in metabolic dysfunction-associated steatotic liver disease in Türkiye**
KAHRAMAN D. C., NALBAT E., ATALAY R., İDİLMAN R.
AASLD-TASL Connect Meeting 2024, İzmir, Türkiye, 16 - 17 Şubat 2024
- III. **Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies**
NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.
4th Open Research Day, Türkiye, 01 Aralık 2023
- IV. **DeepResponse: Large Scale Prediction of Cancer Cell Line Drug Response with Deep Learning Based Pharmacogenomic Modelling**
KAHRAMAN D. C., DOĞAN T.
16th International Symposium on Health Informatics and Bioinformatics (HIBIT 2023), Ankara, Türkiye, 4 - 06 Ekim 2023
- V. **Anti-Cancer and Anti-Stemness Action of Nonsteroidal Anti-Inflammatory Agents: A Special Focus on Hepatocellular Carcinoma**
KAHRAMAN D. C.
3rd International Multidisciplinary Cancer Research Congress, İstanbul, Türkiye, 7 - 10 Eylül 2023
- VI. **Network-based drug repurposing approach identifies novel drugs and drug combinations against HCC**
NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 28 - 29 Nisan 2023
- VII. **Experimental validation of drug responses predicted by deep learning-based bioactivity models in hepatocellular carcinoma cell lines**
KAHRAMAN D. C., DOĞAN T.
15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Türkiye, 20 - 22 Ekim 2022
- VIII. **A Multi-Omics and Machine Learning-Based Predictor of Drug Sensitivity in Cancer**
KAHRAMAN D. C., DOĞAN T.
15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Türkiye, 20 - 22 Ekim 2022
- IX. **Automated prediction of drug response in HCC cell lines with deep learning-based bioactivity modeling and experimental validation**
KAHRAMAN D. C., AKAR E., DOĞAN T.
EACR 2022, Sevilla, İspanya, 20 - 23 Haziran 2022
- X. **Synergistic effect of sorafenib in combination with naproxen on hepatocellular carcinoma cell lines**
AKAR E., KAHRAMAN D. C.
EACR 2022, Sevilla, İspanya, 20 - 23 Haziran 2022
- XI. **A NEW THIADIAZINE DERIVATIVE INDUCES OXIDATIVE STRESS DEPENDENT CELL DEATH IN HEPATOCELLULAR CARCINOMA STEM CELLS**
KAHRAMAN D. C., GÜVEN E. B., AYTAC P., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70
- XII. **A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma**
KAHRAMAN D. C., GÜVEN E. B., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79
- XIII. **Abstract 996: In silico modeling and in vitro validation of undefined off-target of drugs in**

hepatocellular carcinoma

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AACR Annual Meeting 2019, Atlanta, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019

- XIV. **In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma**
Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79
- XV. **Effects of small molecule inhibitors on liver cancer stem cells in comparison with Sorafenib**
KAHRAMAN D. C., ATALAY R.
AASLD-TASL Connect Meeting 2019, İstanbul, Türkiye, 15 - 16 Mart 2019
- XVI. **Identification of interleukin 8 as a cancer stem cell enrichment stimulating factor in HCC**
KAHRAMAN D. C., ATALAY R.
11th International Symposium on Health Informatics and Bioinformatics (HIBIT 2018), Antalya, Türkiye, 25 - 27 Ekim 2018
- XVII. **Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib**
Kahraman D. C., Kahraman T., ATALAY R.
American Association for Cancer Research Annual Meeting 2018, Chicago, Amerika Birleşik Devletleri, 12 - 18 Nisan 2018, cilt.78, ss.3937
- XVIII. **Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells**
KAHRAMAN D. C., ATALAY R.
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, Amerika Birleşik Devletleri, 26 - 30 Ekim 2017
- XIX. **Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells**
Kahraman D. C., ATALAY R.
AACR-NCI-EORTC International Conference, Philadelphia, 26 - 30 Ekim 2017
- XX. **Potency of Interleukin 8 Blockade in Prevention of Liver Cancer Stem Cell Enrichment**
KAHRAMAN D. C., ATALAY R.
5th International BAU Drug Design Congress, İstanbul, Türkiye, 19 - 21 Ekim 2017
- XXI. **ANTICANCER EFFECTS OF NEW INDOLE –PYRAZOLE AND ONDOLE-OSOXAZOLE HYBRIDS DESIGN, SYNTHESIS AND EVALUATION OF ACTIVITY**
Hawash M. M., Kahraman D. C., ATALAY R., BAYTAŞ S.
2nd International Gazi Pharma Symposium, 11 - 13 Ekim 2017
- XXII. **HEPATOCELLULAR CARCİNOMA TERAPEUTICS: SYNTHESIS AND BIOLOGICAL EVALUATION INDOLE-3-CARBOXAMIDES**
Kılıç E. K., Kahraman D. C., ATALAY R., BAYTAŞ S.
2nd International Gazi Pharma Symposium, 11 - 13 Ekim 2017
- XXIII. **Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation**
Hawash M., Kahraman D. C., ATALAY R., BAYTAŞ S.
26th ISHC Congress on Heterocyclic Chemistry, 3 - 08 Eylül 2017
- XXIV. **Dielectrophoretic Spectra of CD133+/EpCAM+ HUH7 Cancer Stem Cells and HUH7 Cancer Cells**
Çağlayan Z., Demircan Yalçın Y., Özkayar G., Kahraman D. C., Atalay R., Özgür E., Külâh H.
Dielectrophoresis 2016, Massachusetts, Amerika Birleşik Devletleri, 13 - 15 Temmuz 2016, ss.1-4
- XXV. **Sequential treatment of HCC cells with PI3K Akt mTOR pathway inhibitors prior to sorafenib attenuates cancer stem cell population**
Kahraman D. C., Kahraman T., ATALAY R.
EACR 27, 1 - 04 Temmuz 2016, cilt.61, ss.77

- XXVI. **Sequential treatment of HCC cells with mTOR pathway inhibitors prior to Sorafenib attenuates cancer stem cell enrichment**
KAHRAMAN D. C., ATALAY R.
24th Biennial Congress of the European Association for Cancer Research, Manchester, İngiltere, 9 - 12 Temmuz 2016
- XXVII. **Recent Advances in Cancer Stem Cell Research**
KAHRAMAN D. C.
COST Action CM1106 4th Workshop, Venedik, İtalya, 10 - 11 Mart 2016
- XXVIII. **Bioactivities of small molecule kinase inhibitors in liver cancer stem cells**
KAHRAMAN D. C., ATALAY R.
COST Action CM1106 3rd Working Group Meeting, ATİNA, Yunanistan, 26 - 27 Mart 2015
- XXIX. **Biological Evaluation of New Pyrazole Derivatives for Novel Therapeutic Opportunities of Hepatocellular Carcinoma**
KAHRAMAN D. C., BAYTAŞ S., ATALAY R.
MolBiyKon 2014, İzmir, Türkiye, 10 - 12 Temmuz 2014
- XXX. **Identification of Novel Small Molecule Kinase Inhibitors Against Liver Cancer Stem Cells**
KAHRAMAN D. C., ATALAY R.
EACR Sponsored 2nd Anticancer Agents Congress and 5th Multidisciplinary Cancer Research Congress, Muğla, Türkiye, 23 - 25 Nisan 2014
- XXXI. **Enrichment of cancer stem cell characteristics of liver cancer cells by prolonged drug selection and identification of cytotoxic activity of new drug candidates**
KAHRAMAN D. C., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.
International Multidisciplinary Symposium on Drug Research and Development (DRD2013), Antalya, Türkiye, 28 - 30 Kasım 2013

Desteklenen Projeler

2023 - 2026	Hepatosellüler Karsinomada Hippo Sinyal Yolağı Hedefli Bileşiklerin Mekanizmasının Aydınlatılması, TÜBİTAK Projesi
2022 - 2025	Öncü Bileşik Optimizasyonu ile Tasarlanan Antikanser Etkili Olabilecek Yeni Bileşiklerin Sentezi, Yapı-Etki İlişkileri ve Moleküler Etki Mekanizmalarının İncelenmesi, TÜBİTAK Projesi
2021 - 2024	Az Biyoaktif Bileşik Verisi Olan Proteinlere Karşı Sanal Tarama için Derin Öğrenme Modelleri (Azderin), TÜBİTAK Projesi
2019 - 2023	İlaçların Daha Önce Tanımlanmamış Hedef Dışı Etkilerinin Hesaplamalı System Biyolojisi Yöntemleri ile Modellenmesi ve Hepatosellüler Kanserde Doğrulanması, TÜBİTAK Projesi
2020 - 2022	Derin Öğrenme Bazlı Farmakogenomik Modelleme ile Geniş Çaplı Kanser Hücre Hattı İlaç Yanıt Tahmini, Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) Araştırma Projesi

Bilimsel Dergilerdeki Faaliyetler

2024 - Devam Ediyor TURKISH JOURNAL OF GASTROENTEROLOGY, Yardımcı Editör/Bölüm Editörü

Bilimsel Kuruluşlardaki Üyelikler / Görevler

2019 - Devam Ediyor	American Association for the Study of Liver Diseases (AASLD), Üye
2019 - Devam Ediyor	Türk Karaciğer Araştırmaları Derneği, Üye
2017 - Devam Ediyor	American Association for Cancer Research (AACR), Üye
2016 - Devam Ediyor	Moleküler Kanser Araştırma Derneği (MOKAD), Üye
2016 - Devam Ediyor	European Association for Cancer Research (EACR), Üye

Bilimsel Arařtırma / alıřma Grubu Üyelikleri

2016 - Devam Ediyor Kanser Sistem Biyolojisi Laboratuvarı, <https://i.metu.edu.tr/cansyl>, Orta Doęu Teknik Üniversitesi, Turkey

Metrikler

Yayın: 54

Atıf (WoS): 523

Atıf (Scopus): 560

H-İndeks (WoS): 14

H-İndeks (Scopus): 13

Ödüller

Eylül 2023	Young Basic Cancer Researcher Award, Moleküler Kanser Arařtırmaları Derneęi (Mokad)
Aęustos 2019	International Early Career Investigator Award, American Association For The Study Of Liver Diseases
Mayıs 2019	Special Mention Poster Award, Enformatik Enstitüsü, Metu
Ekim 2017	Best Poster Award, 5Th International Bau Drug Design Congress